

Special Issue

Advances in Salivary Gland Carcinoma

Message from the Guest Editors

Salivary gland malignancies represent one of the most complex groups of tumors from a pathological point of view. They show a striking range of morphological diversity between different tumor types. In fact, all the WHO classifications that have occurred over time report more than 20 histotypes. Furthermore, the rarity of some of these histotypes needs a skilled pathologist for diagnosis. Parotid tumors are far more common than neoplasms in the other sites (70–80%), but only 20% are malignant. Approximately 50% of the tumors in the submandibular gland and 70% of those in the minor salivary glands are malignant. Because of the high frequency of parotid tumors, despite the low rate of malignant ones, parotid malignancies are more common than those of other salivary glands. These and other topics related to salivary gland carcinomas will be covered in this Special Issue.

Guest Editors

Dr. Giulio Cantù

Prof. Dr. Laura D. Locati

Prof. Dr. Luiz P. Kowalski

Deadline for manuscript submissions

closed (31 August 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/149150

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)